GSK, J&J, and AZ head this year's access to medicines rankin...

The 2022 edition of the Access to Medicine Index (ATMI) – which places the top 20 pharma companies for their efforts to improve delivery of medicines to lower income countries – sees GSK re

Spotlight on women in pharma: Şeyda Atadan Memiş, Takeda

As part of our Women in Pharma series, where we talk to leading figures in the life sciences, we hear from Şeyda Atadan Memiş, recently appointed general manager for Takeda UK and

Applying a payer lens to your early pipeline planning

Understanding commercial and market access risks and opportunities at an early stage in biopharmaceutical product development is essential for optimizing commercial success.

FDA panel backs AZ’s PT027 asthma rescue drug, but in adults...

AstraZeneca has moved a step closer to bringing a first-in-class drug to market in the US that can be used to reduce severe asthma attacks, after an FDA advisory committee voted in favour o

Report: Reinventing product and portfolio value for the biop...

Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing ne

Practical advice for Early Scientific Advice (ESA) in HTA su...